Kaftrio, an innovative triple gene therapy to fight cystic fibrosis, will be generalized in France for children, while until now it was only available for patients over the age of 12, Health Minister Francois announced on December 17 Braun. Provided in the form of tablets for life, this combination of three molecules reduces the effects of the disease, especially pulmonary trauma. This is a major breakthrough. Indeed, the disease of genetic origin, which deteriorates the respiratory and digestive systems, was often fatal for children and adolescents. The cure is a revolution capable, for many patients, of transforming cystic fibrosis into a chronic and stabilized pathology. This announcement was met with a “feeling of relief,” said David Fiant, president of the Vaincre mucoviscidose association. However, nearly 35% of patients with cystic fibrosis are still waiting for an adequate response.
